Adhesion of Helicobacter pylori to the gastric mucosa is a necessary prerequisite for the pathogenesis of H. pylori-related diseases. In this study, we investigated the GalNAcβ1-4GlcNAc motif (also known as N,N'-diacetyllactosediamine [lacdiNAc]) carried by MUC5AC gastric mucins as the target for bacterial binding to the human gastric mucosa. The expression of LacdiNAc carried by gastric mucins was correlated with H. pylori localization, and all strains tested adhered significantly to this motif. Proteomic analysis and mutant construction allowed the identification of a yet uncharacterized bacterial adhesin, LabA, which specifically recognizes lacdiNAc. These findings unravel a target of adhesion for H. pylori in addition to moieties recognized by the well-characterized adhesins BabA and SabA. Localization of the LabA target, restricted to the gastric mucosa, suggests a plausible explanation for the tissue tropism of these bacteria. These results pave the way for the development of alternative strategies against H. pylori infection, using adherence inhibitors.
Helicobacter pylori are gram-negative bacteria that infect over half of the world's population. The species was first identified in 1983 by Marshall and Warren in the gastric mucosa of a patient with chronic gastritis [1] . Most individuals acquire H. pylori in childhood. These bacteria induce a chronic inflammation of the underlying mucosa, which tends to persist indefinitely unless treated. In absence of treatment, these pathogens participate in the development of 3 clinically important upper gastrointestinal diseases: gastroduodenal ulcer, gastric carcinoma (except cancer of the gastric cardia), and mucosa-associated lymphoid tissue lymphoma [2] . The ability of H. pylori to cause disease depends on a variety of host, environmental, and bacterial factors.
H. pylori colonize the gastric mucosa by adhering to epithelial cells and the mucus layer lining the gastric epithelium. The mucus layer is a powerful barrier that protects tissues from mechanical damage, as well as chemical erosion from pepsin and HCl. Together with water, its main components are large glycoproteins called mucins, which consist of a large linear protein core (apomucin) carrying hundreds of branched chains of oligosaccharides along its entire length. The extreme length of these molecules, together with their high degree of glycosylation (>50% of their total weight) and their negative charge, are major determinants of their ability to form gels. Also, mucins undertake receptor-ligand interactions and communicate information about external cell conditions through signal transduction [3] .
Most H. pylori reside within the mucous gel layer of the stomach that covers the apical surface of the gastric epithelium, with approximately 20% of the population found to bind directly to gastric epithelial cells [4] . Different molecular mechanisms have been proposed to explain bacterial adherence to the gastric mucins and cells. Among them, 2 H. pylori adhesins, BabA and SabA, have been well characterized with respect to their target specificities. BabA (the blood group antigen-binding adhesin) is specific for fucosylated blood group antigens H-type 1 and Le b but also extends its spectrum of binding to terminal residues of blood group A and B glycan determinants [5] [6] [7] . SabA (the sialic-acid binding adhesin) binds the sialyl Le a and sialyl Le x antigens [8, 9] . Although BabA and SabA are the most prevalent adhesins studied so far, not all H. pylori strains express these adhesins functionally [10, 11] . This implies that other bacterial entities must be involved in adhesion of these bacteria to gastric mucins and cells. Possible candidates include H. pylori outer membrane proteins (OMPs), but because the family is extensive, their functional role continues to be investigated. In this work, we have identified and characterized a bacterial adhesin of H. pylori that binds specifically the lacdiNAc motif located on MUC5AC mucins, which we have termed "LabA" (ie, lacdiNAc-binding adhesin). The role of LabA in H. pylori gastric tropism and the use of analogs or derivatives of lacdiNAc to inhibit bacterial adhesion and thus as novel tools for the treatment of H. pylori infection are discussed.
METHODS

Human Samples and Mucin Preparation
Gastric tissues from 32 individuals were collected by Dr Jacques Bara according to protocols approved by the French national ethics committee. A summary of the age, sex, and blood group status of the donors is given in Supplementary Table 1 . Mucins were purified as described before [12] .
Release of Oligosaccharides From Mucin by Alkaline Borohydride Treatment
The gastric mucins were subjected to β elimination under reductive conditions (ie, 0.1 M NaOH and 1 M NaBH 4 for 24 hours at 45°C).
Fractionation of the Oligosaccharide Alditols by HighPerformance Liquid Chromatography (HPLC)
The mixture of oligosaccharides was subjected to fractionation by HPLC (Dionex Chromeleon System, Sunnyvale, CA) on a primary amino-bonded silica column (Supelcosyl, LC-NH 2 , 4.6 × 250 mm, Supelco, Bellefonte, CA). The column was equilibrated with the initial solvent, using a mixture of acetonitrile H 2 O (ratio, 80:20 by volume) with a flow rate of 1 mL/minute. After the injection, a linear gradient was applied for 80 minutes to achieve a ratio of 40:60 by volume, which was kept as isocratic conditions for 20 minutes. A second HPLC step on a C18 reverse-phase column was conducted for the fraction containing the glycan of interest. Oligosaccharides were eluted with H 2 O. Oligosaccharides were detected by UV spectroscopy at 200 nm, using an UVD 170U detector (Dionex).
Analysis of Glycans by Nanoelectrospray Mass Spectrometry
All analyses were performed on a Q-STAR Pulsar quadrupole time-of-flight (TOF) mass spectrometer (Applied Biosystems/ MDS Sciex, Toronto, Canada) fitted with a nanoelectrospray ion source (Protana, Odense, Denmark), as described previously [13] . 
Analysis of Glycans by
Immunohistochemical Analysis
Human biopsy specimens were formalin fixed and paraffin embedded. Sections with a thickness of 3 μm were prepared from paraffin blocks of formalin-fixed specimens. Heat pretreatment of the sections for 10 minutes was performed in citrate buffer ( pH 4.0). Negative-control slides were incubated without primary antibodies. Sections were incubated overnight with primary antibodies against MUC5AC (1:100), MUC6 (1:10), or lacdiNAc (1:100). After washing, Alexa Fluor-conjugated anti-mouse (1:500) or anti-rabbit (1:500) secondary antibody was added as appropriate and incubated for 60 minutes. Slides were counterstained with DAPI.
For double-immunofluorescent analysis of intestinal metaplasia, samples were treated as described above for singleimmunofluorescent labeling with MUC5AC antibody (CLH2, diluted 1:5), followed by incubation with a second primary antibody against MUC2 (PMH1, diluted 1:10) or lacdiNAc (diluted 1:100) overnight. After washing, sections were incubated with Texas red-conjugated goat anti-mouse immunoglobulin M for 45 minutes. Slides were counterstained with DAPI.
For bright-field evaluation of lacdiNAc expression, the horseradish peroxidase (HRP)-avidin-biotin complex method was used. Briefly, after deparaffination and rehydration, endogenous peroxidase activity was blocked with 3% H 2 O 2 in methanol. Then samples were incubated with normal rabbit serum diluted 1:5 in phosphate-buffered saline (PBS) containing 10% bovine serum albumin for 30 minutes. Sections were then incubated with anti-lacdiNAc (dilution, 1:100). The slides were subsequently washed in PBS and incubated for 30 minutes with biotinylated rabbit anti-mouse antibody (dilution, 1:200) before incubation with HRP-avidin-biotin complex (Vectastain Elite ABC kit, Burlingame, CA), according to the manufacturer's recommendations. Staining was performed with 3,3′-diaminobenzidine tetrahydrochloride containing 0.02% hydrogen peroxide. Slides were counterstained with Mayer's hematoxylin. Negative controls were performed by replacing primary antibody with PBS.
Animal Tissue Samples
Stomachs from 6-8-week-old C57Bl/6 mice and from 3-monthold Sprague Dawley rats were obtained according to animal experimentation guidelines. Every specimen was fixed in Carnoy's solution and embedded in paraffin wax. Serial sections with a thickness of 3 µm were cut and used for immunohistochemical analysis.
Bacterial Strains and Growth Media
H. pylori strains B128 [15] , 26695 [16] , J99 [17] , G27 [18] , P12 [19] , and B38 [20] were cultivated on blood agar plates or brainheart infusion medium with 10% decomplemented fetal calf serum, with or without supplementation, with an antibioticantifungal mix (0.31 µg/mL of polymyxin B, 2.5 µg/mL of amphotericin B, 12.5 µg/mL of vancomycin, and 6.25 µg/mL of trimethoprim) and appropriated antibiotics (20 µg/mL of kanamycin, 5 µg/mL of apramycin, or 5 µg/mL of chloramphenicol) at 37°C in a microaerophilic atmosphere.
Assay of H. pylori Adhesion to Gastric Mucosa
H. pylori was labeled with fluorescein isothiocyanate and adhesion assays were performed as previously described [14] . For inhibition assays, the bacteria (50 µL of the suspension containing 10 8 bacteria/mL diluted 2.5-fold in protein-free blocking buffer)
were preincubated 2 hours with lacdiNAc or Lewis b (50 µL of glycans at 1 mM). Evaluation of bacterial binding was estimated by determining the number of adherent bacteria under 400 × magnification. Each value represents the mean value for at least 5 different fields.
Identification by Proteomic Analysis of LabA
Bacterial lysates from B128 and 26695 strains were incubated overnight with or without free lacdiNAc glycan at 2 mM before co-incubation with human purified gastric mucins. After centrifugation (2655 g for 2 minutes) to pellet insoluble mucins and bound proteins, the supernatant was collected and proteins were separated on 7.5% gel electrophoresis. Differentially expressed proteins were submitted to "in gel" trypsin digestion.
Protein identification was performed using peptide mass fingerprinting on a matrix-assisted laser desorption/ionization TOF/ TOF mass spectrometer (AB Sciex TOF TOF 5800, Applied Biosystems, Foster City, CA). Proteins were identified using Protein Prospector (available at: http://prospector.ucsf.edu/) from protein databases (UniProt release 2011_03 -8 Mar 2011) and are numbered according to the HPB128155g82 peptide sequence, as follows: (1) aa45-GIQDLSDSYER-aa55, (2) aa72-QSADPNAINNAR-aa83, (3) aa360-AQAEILNR-aa367, (4) aa514-TQELGSNPFR-aa523, (5) aa514-TQELGSNPFRRaa524, and (6) aa561-YYGFVDYNHTYNK-aa573.
Construction of the OMP Mutant
The bank of the entire set of open reading frames of H. pylori strain 26695 was previously cloned into DH1 and inactivated systematically with the miniTn3-Km [21] . The oipA (hp0636) and hopD (hp0025) genes were inactivated using the miniTn3-Km strategy because these genes did not have any other downstream genes cotranscribed. Polymerase chain reaction was used to confirm the miniTn3-Km insertion.
RESULTS
Immunolocalization of the LacdiNAc Motif Along the Gastrointestinal Tract
The expression of lacdiNAc at the luminal surface of different human organs (stomach, colon, small intestine, salivary glands, and bronchial mucosa) was performed by immunohistochemical analysis. Double immunostaining was performed with polyclonal anti MUC5AC antibody (LUM5-1) and monoclonal anti MUC6 (CLH-5) or lacdiNAc antibodies (273-3F2). Among the human gastric tissues examined, the expression of lacdiNAc was absent in cardiac glands ( Figure 1A ), limited to the surface of the fundic mucosa ( Figure 1B) , and expressed more deeply in pyloric glands ( Figure 1C ). In the stomach body, lacdiNAc antibody stained the superficial and foveolar epithelium, with staining extending to the middle of the mucosal layer (Figure 1D ). Where lacdiNAc was detected, it always colocalized with MUC5AC mucins. However, MUC5AC immunoreactivity continued deeper into all glands, indicating that this moiety was not always present on MUC5AC. No colocalization with MUC6 was detected either in the mucous cells of the neck zone or in the parietal cells, nor was there any detection of MUC5AC ( Figure 1E ). In humans, MUC5AC is also present in mucus from the vagina and lung, as well as in the stomach. However, lacdiNAc was only observed in association with MUC5AC in the stomach (data not shown). One exception was in the metaplasia of duodenal mucosa, which is of gastric origins (Figure 1F ) . This is medically relevant in the sense that H. pylori actually can colonize the duodenum with gastric metaplasia. Likewise, in the incomplete type of intestinal metaplasia, which can be colonized by H. pylori [22] and is characterized by the coexpression of gastric and intestinal mucins, lacdiNAc and MUC5AC coexpression was observed (Figure 2A ). In contrast, the complete type of intestinal metaplasia of the gastric mucosa, which is characterized by loss of expression of the gastric mucins MUC1, MUC5AC, and MUC6 and by de novo expression of intestinal MUC2 mucin [23] , is not colonized by H. pylori [22] . No lacdiNAc expression was observed in these corresponding samples ( Figure 2B ). Therefore, we hypothesize that the lacdiNAc motif expressed on MUC5AC could play a role in H. pylori colonization in humans.
To complete this work, expression of lacdiNAc was assessed in stomachs from 3 rodent species known to be potentially colonized by various Helicobacter species. In the gastric mucosa of mice and rats (data not shown), the staining resembled that seen in the human-derived tissue, with expression of lacdiNAc limited to the superficial foveolar epithelium. In gerbils, lacdiNAc was also expressed at the surface of the crypts. However lacdiNAc detection did not colocalize with MUC5AC, because this mucin type was exclusively expressed at the bottom of the crypts (Figure 3) .
A Unique lacdiNAc Containing O-glycan Mediates Binding of H. pylori to Gastric Mucosa
The O-glycans carrying the lacdiNAc motif were isolated from purified mucins to study the binding of H. pylori to lacdiNAc. Gastric mucins from 32 healthy adults were isolated by a combination of isopycnic density gradient centrifugation and gel chromatography. Oligosaccharides were released by reductive β elimination, and the mixture of O-glycans was fractionated by HPLC (Supplementary Figure 1A) . The fraction containing the glycan of interest was submitted to a further fractionation step on a hydrophobic column, allowing separation of the lacdiNAc glycan from others (Supplementary Figure 1B) . These experiments not only provided a pure preparation of oligosaccharides but also allowed the relative abundance of this glycan to be determined in each human sample tested (Supplementary Table 1 ). The glycan carrying lacdiNAc represented around 7% of human adult gastric mucin O-glycans. Its presence in gastric mucosa was recently described on the basis of mass spectrometry data [24] , and we confirmed its structure, Fucα1-2Galβ1-3 (GalNAcβ1-4GlcNAcβ1-6)GalNAcol, by performing extensive NMR analysis (Supplementary Figure 1C and 1D) .
The binding specificities of 6 H. pylori strains to mucosa were assessed in competition assays, using either soluble commercially available glycoconjugates (lacdiNAc MP and Le b ) or the purified natural glycan carrying the lacdiNAc motif. Significant inhibition of H. pylori binding by 0.5 mM of lacdiNAc containing soluble free oligosaccharides was observed for all tested strains except B128. The levels of inhibition varied between strains and ranged from 26.2% to 61.6% for commercial lacdiNAc, which increased to 28.3%-73.2% for the purified human gastric oligosaccharide ( Figure 4 ). Our data were in agreement with previous studies for competitive inhibition by Le b [7, 8] ,
showing a strain-dependent variation in binding ( Figure 4E ). For example, H. pylori 26695 adhered strongly to lacdiNAc glycoconjugates, and preincubation of the bacteria with lacdiNAc completely abolished bacteria binding, whereas only a weak inhibition was observed for Le b (Figure 4A-D) .
In complementary experiments, sections of human gastric mucosa were pretreated with monoclonal antibodies against the Le b and the lacdiNAc moieties and further assessed for bacterial binding. As an example, data obtained with J99 showed an approximately 65% reduction in bacterial binding when the gastric tissue sections were preincubated with either anti Le b or anti lacdiNAc ( Figure 4F ). As expected, no reduction in the binding of strain 26695 could be observed when tissue sections were pretreated with anti Le b , whereas 70% of the binding was annihilated by anti-lacdiNAc antibody. Bearing in mind that strain 26695 does not express functional BabA and SabA adhesins, it can be hypothesized that lacdiNAc is recognized by yet uncharacterized adhesins. Strong inhibition of adhesion (about 75%) is observed with strain B128 when gastric mucosa is preincubated with monoclonal anti lacdiNAc or Le b antibodies.
This result seems to contradict the data obtained when bacteria were preincubated with the free corresponding glycans at 0.5 mM (Figure 4B-D) . However, about the same rate of inhibition was observed when bacteria were preincubated with these glycans at 25 mM (data not shown).
Purification and Identification of an Adhesin With lacdiNAc Binding Specificity
To better understand how H. pylori adheres to gastric mucosa, we attempted to identify and purify the adhesin of H. pylori involved Figure 3 . Evaluation of lacdiNAc expression in gerbil gastric mucosa. Expression of lacdiNAc (in green) was observed in the superficial foveolar (S) epithelium of the gerbil gastric mucosa but was not harbored by MUC5AC (in red). in recognition of lacdiNAc. Bacterial lysates from H. pylori strains B128 and 26695 were incubated with pure gastric mucins in the presence or absence of free lacdiNAc glycan provided as a binding competitor ( Figure 5A-C) . Proteins left unbound to gastric mucins were separated by 7.5% SDS-PAGE. One protein, with a size of 77 kDa, was significantly more abundant in the competitive experiments, corresponding to the putative adhesin (Figure 5D ). The band was excised from the gel for proteomic analysis. Ten peptides were identified on the basis of peptide mass, of which 6 were sequenced ( Figure 5E ). All of the sequenced peptides matched peptides encoded by HP0025 gene in strain 26695. This gene belongs to the large hop family of H. pylori OMP genes and was identified as hopD [25] . We renamed this protein "LabA" because of its binding properties.
LabA Is Involved in H. pylori Binding to Gastric Mucosa In Vivo
To assess functional binding of the LabA adhesion, we generated a labA deletion strain of H. pylori B128 ( Figure 6A ). In situ assays showed a strong reduction of binding of the H. pylori ΔlabA strain to the surface of gastric mucosa, compared with the wild-type strain ( Figure 6C and 6D). Moreover, preincubation of ΔlabA with free lacdiNAc did not modify the binding ( Figure 6E and 6F), in contrast to what was found with the wild-type strain. In further support of a specific interaction between LabA and lacdiNAc, adhesion of ΔlabA ( Figure 6G ) was similar to that of the wild-type strain in the deeper gastric mucosa, where MUC5AC but not lacdiNAc is expressed ( Figure 6H ). To assess the specificity of this effect, a second deletion mutant strain of H. pylori B128 was generated for the gene oipA (denoted ΔoipA; Figure 6B ). Indeed, oipA encodes an OMP characterized to play a role in H. pylori adhesion but for which the recognition motif has not yet been identified. Preincubation with lacdiNAc profoundly reduced the binding of the ΔoipA mutant to the gastric mucosa, in contrast to that seen with the ΔlabA strain (Supplementary Figure 2) .
DISCUSSION
H. pylori exhibits strict host and tissue specificity. It colonizes exclusively gastric tissues from humans and a few other species. Tropism of the bacteria for the stomach is unlikely to be explained by the strongly acidic conditions generated by the stomach; indeed, the area of gastric metaplasia in the duodenum, incomplete type of intestinal metaplasia, and gastric tissue in Meckel's diverticulum are all efficiently colonized [26, 27] . BabA and SabA are 2 well-characterized adhesins of H. pylori that bind Le b blood group antigens and sialylated Le a or Le x determinants, respectively. However these glycan motifs are not restricted to the gastric mucosa and are also found on mucins from the digestive tract. Therefore, functional binding of these adhesins cannot explain the restricted tropism of this microorganism. In this study, we have demonstrated that lacdiNAc is expressed at the surface of the gastric mucous cells of humans and several animal species and colocalizes with gastric MUC5AC (this result was also confirmed by structural analysis of the glycosylation pattern of purified mucins) and H. pylori colonization under physiological conditions. In gastric and intestinal pathologies, characterized by both expression of MUC5AC and H. pylori adhesion, strong expression of lacdiNAc was observed. In contrast, in organs devoid of H. pylori colonization, lacdiNAc oligosaccharides were never detected, whether or not these organs expressed MUC5AC. Previous studies have provided evidence that MUC5AC constitutes a specific receptor for the bacteria but stopped short of identifying which peptidic or glycosylated domain of the mucin is implicated in the binding of H. pylori [18] . From in situ inhibition assays, we have demonstrated a strong adhesion of the bacteria to lacdiNAc. We suggest that this interaction may underlie the previously unexplained tropism of the bacteria for gastric tissue and its colocalization with MUC5AC. We have shown that the lacdiNAc carrying glycan is exclusively expressed on gastric mucins and strongly inhibits H. pylori adherence in situ. This may explain the specific and restricted tropism of H. pylori for gastric mucosa.
We have identified LabA as the H. pylori adhesin involved in the recognition of the lacdiNAc motif. Understanding the regulation of expression of lacdiNAc in physiopathological conditions will give information about the role played by the glycan in gastric homeostasis and its evolutionary significance. As antibiotic resistance associated with H. pylori eradication is increasingly observed, there is a pressing need to develop alternative strategies [29] . Our discovery offers the possibility for new therapeutic alternatives to antibiotics to eradicate or control of H. pylori based on inhibition of bacterial adhesion. Since it is possible to chemically synthesize lacdiNAc, the present study provides a basis for development of analogs or derivatives of this glycan motif to treat H. pylori infection.
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